A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
This phase I trial is studying the safety and best dose of GC33 in patients with advanced or metastatic liver cancer.
Advanced or Metastatic HCC
DRUG: GC33
Determine the safety and tolerability of escalating doses of GC33, Continuously
Characterize the pharmacokinetics of GC33, Continuously|Perform a preliminary assessment of anti-tumor activity of GC33, Continuously
This is a Phase I open-label dose escalation study of GC33 in patients with advanced or metastatic HCC. This study is designed to evaluate safety, tolerability, pharmacokinetics, and preliminary assessment of anti-tumor activity. Enrollment will proceed until a maximum tolerated dose (MTD) and a recommended Phase II dose has been established.